DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery

Information source: Queen's University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Endophthalmitis

Intervention: gatifloxacin ophthalmic (ZYMAR) (Drug)

Phase: N/A

Status: Suspended

Sponsored by: Queen's University

Official(s) and/or principal investigator(s):
Sherif El-Defrawy, MD PhD FRCSC, Principal Investigator, Affiliation: Queen's University, Hotel Dieu Hospital, Kingston General Hospital

Summary

Postoperative endophthalmitis, a possible severe complication of cataract surgery, is an infection of the anterior chamber of the eye caused by bacterial contamination and colonization through surgical incisions. Bacteria are thought to originate mainly from the patient’s skin and studies show that bacteria are commonly found in the anterior chamber following surgery. However, innate immune defences are usually able to control and eliminate bacterial growth before postoperative endophthalmitis occurs. Also, due to the low incidence of postoperative endophthalmitis, it is difficult to accurately evaluate preventative methods. This study will examine the efficacy of topical preoperative administration of gatifloxacin (a new fourth generation fluoroquinolone antibiotic) on reduction of bacterial contamination of the anterior chamber following cataract surgery. If the antibiotic is shown to lower bacteria count in cultures from anterior chamber fluid, it has the potential to lower the incidence of postoperative endophthalmitis.

Patients undergoing cataract surgery will be notified and asked to participate in the study by the physician in advance of the surgery, provided they do not possess any exclusion criteria. The participants will be randomly split into two groups; one group will receive topical application of gatifloxacin prior to surgery, while the other group will receive no eye drops. During surgery, a small sample of anterior chamber fluid will be removed from the eye and cultured in both broth and enrichment media for all subjects. Bacterial growth, i. e., colony forming units (CFUs), will be used as an indicator of the bacterial contamination of the fluid.

Clinical Details

Official title: The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery.

Study design: Prevention, Randomized, Open Label, Active Control, Single Group Assignment

Primary outcome: Difference in bacterial colony forming units (CFUs) between treatment (gatifloxacin) and no treatment group

Secondary outcome:

Bacterial sensitivity

Patient comfort

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Cataract surgery on first eye (i. e., first cataract surgery.

Exclusion Criteria:

- uveitis,

- herpetic eye disease,

- corneal ulceration,

- severe blepharitis,

- past trauma to the eye,

- complicated cataract surgery (e. g., posterior capsule rupture),

- previous intraocular surgeries.

Locations and Contacts

Hotel Dieu Hospital, Kingston, Ontario K7L 5G2, Canada
Additional Information

Starting date: June 2006
Ending date: May 2007
Last updated: May 17, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012